Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation

A Correction to this article was published on 19 April 2021

This article has been updated

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Flow chart and process of treatment.

Change history

References

  1. 1.

    Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol. 2019;37:1479–89. https://doi.org/10.1200/jco.18.02151.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev. 2010;36:528–38. https://doi.org/10.1016/j.ctrv.2010.03.004.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, Shaw B, et al. A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant. 2015;50:62–7. https://doi.org/10.1038/bmt.2014.227.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107:138–50. https://doi.org/10.1007/s12185-017-2364-4.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Stahl M, Goldberg AD. Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets. Curr Oncol Rep. 2019;21:37. https://doi.org/10.1007/s11912-019-0781-7.

    Article  PubMed  Google Scholar 

  6. 6.

    Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9:370–83. https://doi.org/10.1158/2159-8290.Cd-18-0774.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Alfayez M, Borthakur G. Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges. Expert Rev Hematol. 2018;11:373–89. https://doi.org/10.1080/17474086.2018.1459184.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14:3044–51. https://doi.org/10.1158/1078-0432.Ccr-07-4079.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143–53. https://doi.org/10.1056/NEJMoa1601202.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Song-Bai Liu or Sheng-Li Xue.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: the representation of Figure 1 was incorrect.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qian, CS., Ma, X., Wang, J. et al. PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation. Bone Marrow Transplant 56, 1003–1005 (2021). https://doi.org/10.1038/s41409-020-01130-8

Download citation

Search

Quick links